These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34871053)

  • 1. In non-critically ill patients with COVID-19, therapeutic anticoagulation improved survival to discharge without organ support.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC134. PubMed ID: 34871053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In critically ill patients with COVID-19, therapeutic anticoagulation did not increase organ support-free days.
    Donato AA
    Ann Intern Med; 2021 Dec; 174(12):JC135. PubMed ID: 34871054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulation for COVID-19 Patients: A Bird's-Eye View.
    Kreidieh F; Temraz S
    Clin Appl Thromb Hemost; 2021; 27():10760296211039288. PubMed ID: 34595937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
    Bikdeli B; Garcia DA
    Ann Intern Med; 2022 Feb; 175(2):JC16. PubMed ID: 35099997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In COVID-19, escalated- vs. prophylactic-dose anticoagulation does not reduce mortality and increases major bleeding.
    Chaudhuri D; Rochwerg B
    Ann Intern Med; 2022 Feb; 175(2):JC18. PubMed ID: 35099996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In high-risk inpatients with COVID-19, therapeutic- vs. standard-dose heparin reduced thromboembolism or death at 30 d.
    Bikdeli B; Garcia DA
    Ann Intern Med; 2022 Feb; 175(2):JC17. PubMed ID: 35099994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Another new application of heparin in COVID-19: more than anticoagulation and antiviral.
    Yu X
    J Investig Med; 2021 Aug; 69(6):1258. PubMed ID: 34112704
    [No Abstract]   [Full Text] [Related]  

  • 8. Continuation of therapeutic dose heparin for critically ill patients with COVID-19.
    Bradbury CA; Lawler PR; McVerry BJ; Zarychanski R;
    Intensive Care Med; 2023 Jul; 49(7):873-875. PubMed ID: 37256341
    [No Abstract]   [Full Text] [Related]  

  • 9. Dialysis circuit clotting in critically ill patients with COVID-19 infection.
    Khoo BZE; Lim RS; See YP; Yeo SC
    BMC Nephrol; 2021 Apr; 22(1):141. PubMed ID: 33879086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In uninfected household contacts of patients with COVID-19, REGEN-COV reduced symptomatic COVID-19 at 28 d.
    Lau D; Saxinger L
    Ann Intern Med; 2022 Jan; 175(1):JC5. PubMed ID: 34978854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study.
    Ferguson J; Volk S; Vondracek T; Flanigan J; Chernaik A
    J Clin Pharmacol; 2020 Nov; 60(11):1411-1415. PubMed ID: 32885463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The single-dose J&J vaccine had 67% efficacy against moderate to severe-critical COVID-19 at ≥14 d.
    Sacks HS
    Ann Intern Med; 2021 Jul; 174(7):JC75. PubMed ID: 34224270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In noncritical COVID-19, therapeutic vs. prophylactic anticoagulation did not reduce a composite adverse clinical outcome at 30 d.
    DeLoughery TG
    Ann Intern Med; 2023 Aug; 176(8):JC93. PubMed ID: 37523703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In COVID-19, therapeutic vs. prophylactic anticoagulation did not improve clinical outcomes and increased bleeding.
    Diep R; Garcia D
    Ann Intern Med; 2021 Oct; 174(10):JC112. PubMed ID: 34606319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
    Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
    Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Learning with COVID-19: what about anticoagulation?].
    Álvarez-Rodríguez E; González González R; Torres-Gárate R; López-Riquelme P; González Martil I; Abad Cuñado V
    An Sist Sanit Navar; 2020 Aug; 43(2):251-254. PubMed ID: 32865189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Novavax vaccine had 90% efficacy against COVID-19 ≥7 d after the second dose.
    Sacks HS
    Ann Intern Med; 2021 Nov; 174(11):JC124. PubMed ID: 34724399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin Dose Intensity and Organ Support-Free Days in Patients Hospitalized for COVID-19.
    Godoy LC; Neal MD; Goligher EC; Cushman M; Houston BL; Bradbury CA; McQuilten ZK; Tritschler T; Kahn SR; Berry LR; Lorenzi E; Jensen T; Higgins AM; Kornblith LZ; Berger JS; Gong MN; Paul JD; Castellucci LA; Le Gal G; Lother SA; Rosenson RS; Derde LPG; Kumar A; McVerry BJ; Nicolau JC; Leifer E; Escobedo J; Huang DT; Reynolds HR; Carrier M; Kim KS; Hunt BJ; Slutsky AS; Turgeon AF; Webb SA; McArthur CJ; Farkouh ME; Hochman JS; Zarychanski R; Lawler PR
    JACC Adv; 2024 Mar; 3(3):100780. PubMed ID: 38938844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic Anticoagulation with Heparin in Patients with Covid-19. Reply.
    Zarychanski R; Lawler PR; Goligher E
    N Engl J Med; 2021 Nov; 385(21):2014. PubMed ID: 34788517
    [No Abstract]   [Full Text] [Related]  

  • 20. Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia.
    Tong SYC; Petersiel N
    Ann Intern Med; 2021 Oct; 174(10):JC111. PubMed ID: 34606317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.